Evidence map›Paper›PMID 33965174›Full record

ArticleTransplantation and cellular therapy2021

Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy: Considerations and Guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee.

Akshay Sharma, Sherif M Badawy, Elizabeth M Suelzer, Hemant S Murthy, Pinki Prasad, Hesham Eissa, Paul A Carpenter, Mehdi Hamadani, Myriam Labopin, Hélène Schoemans and 8 more

Open access · greenAbstract read
In one paragraph

Article in Transplantation and cellular therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 3 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 14 institutions in 4 countries.

Akshay SharmaDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.
Sherif M BadawyDepartment of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Elizabeth M SuelzerMedical College of Wisconsin, Milwaukee, Wisconsin.
Hemant S MurthyDivision of Hematology/Oncology, Mayo Clinic Florida, Jacksonville, Florida.
Pinki PrasadDivision of Pediatric Hematology/Oncology, Louisiana State University Health Sciences Center/Children's Hospital of New Orleans, New Orleans, Louisiana.
Hesham EissaDepartment of Pediatrics, University of Colorado School of Medicine, Blood and Marrow Transplant and Cellular Therapy Program, Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, Colorado.
Paul A CarpenterFred Hutchinson Cancer Research Center and Department of Pediatrics, University of Washington, Seattle, Washington.
Mehdi HamadaniBMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin and Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin.
Myriam LabopinEBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France.
Hélène SchoemansDepartment of Hematology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
André TichelliDivision of Hematology, University Hospital Basel, Basel, Switzerland.
Rachel PhelanDivision of Hematology and Oncology, and BMT, Department of Pediatrics, Medical College of Wisconsin and Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin.
Betty K HamiltonBlood & Marrow Transplant Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
David BuchbinderDivision of Pediatric Hematology, Children's Hospital of Orange County, Orange, California.
Annie ImUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Rebecca HunterDivision of Hematology, University of Colorado Anschutz Medical Center, Aurora, Colorado.
Ruta BrazauskasDivision of Biostatistics, Medical College of Wisconsin and Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin.
Linda J BurnsCenter for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin. Electronic address: lburns@mcw.edu.
Medical College of Wisconsin · USChildren's Hospital Colorado · USChildren's Hospital of Orange County · USCleveland Clinic · USInserm · FRJacksonville College · USKU Leuven · BELouisiana State University · USNorthwestern University · USSt. Jude Children's Research Hospital · USUniversity Hospital of Basel · CHUniversity of Colorado Anschutz Medical Campus · USUniversity of Washington · USUPMC Hillman Cancer Center · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
Hematopopietic Stem Cell TransplantationU01AI069197 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2005 to 2026
$18.9M
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiencyU01AI126612 · NIAID · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S, PULSIPHER, MICHAEL A · 2017 to 2023
$8.5M
Immuno and Epigenetics of Hematopoietic Cell TransplantationR01CA218285 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2017 to 2026
$5.6M
The role of TCOF1 in germline predisposition to and in leukemic transformation of chronic myelomonocytic leukemiaR01CA152108 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Jing Zhang · 2011 to 2026
$5.4M
Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic DataR01AI128775 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JILL Allison HOLLENBACH, STEVEN JOHN MACK · 2017 to 2026
$4.5M
Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell DonorsR01HL131731 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PULSIPHER, MICHAEL A, SWITZER, GALEN E. · 2018 to 2022
$3.6M
Integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantationR01CA215134 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BAKER, KEVIN S, MAJHAIL, NAVNEET S. · 2017 to 2022
$3.6M
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA GenotypesR01HL129472 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI HSU, KATHARINE C · 2015 to 2019
$2.6M
NCATS NIH HHS UL1 TR001422NCI NIH HHS P01 CA111412NCI NIH HHS R01 CA152108NCI NIH HHS R01 CA215134NCI NIH HHS R01 CA218285NCI NIH HHS R01 CA231141NCI NIH HHS U24 CA076518NHLBI NIH HHS K23 HL150232NHLBI NIH HHS R01 HL129472NHLBI NIH HHS R01 HL130388NHLBI NIH HHS R01 HL131731NHLBI NIH HHS R21 HL140314NHLBI NIH HHS U01 HL128568NHLBI NIH HHS U24 HL138660NIAID NIH HHS R01 AI128775NIAID NIH HHS U01 AI069197NIAID NIH HHS U01 AI126612
6 · The paper itself

Abstract

Systematic reviews apply rigorous methodologies to address a prespecified, clearly formulated clinical research question. The conclusion that results is often cited to more robustly inform decision making by clinicians, third-party payers, and managed care organizations about the clinical question of interest. Although systematic reviews provide a rigorous standard, they may be infeasible when the task is to create general disease-focused guidelines comprising multiple clinical practice questions versus a single major clinical practice question. Collaborating transplantation and cellular therapy society committees also recognize that the quantity and or quality of reference sources may be insufficient for a meaningful systematic review. As the conduct of systematic reviews has evolved over time in terms of grading systems, reporting requirements, and use of technology, here we provide current guidance on methodologies, resources for reviewers, and approaches to overcome challenges in conducting systematic reviews in transplantation and cellular therapy.

Indexed as

Hematopoietic Stem Cell TransplantationQuality of LifeSystematic Reviews as TopicBone MarrowTransplantation, HomologousUnited StatesCellular therapyHematopoietic cell transplantationSystematic reviews

Identifiers

PMID33965174
PMCPMC8415092
OpenAlexW3128446990

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.